What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Sell
4
LEGN Quote, Financials, Valuation and Earnings
Last price:
$22.19
Seasonality move
:
-11.27%
Day range:
$22.28 - $23.14
52-week range:
$22.28 - $45.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.52x
P/B ratio:
4.07x
Volume:
1.9M
Avg. volume:
2.2M
1-year change:
-37.11%
Market cap:
$4.1B
Revenue:
$627.6M
EPS (TTM):
-$1.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corp.
|
$275.4M | -$0.12 | 70.49% | -33.34% | $72.31 |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.5M | -$0.34 | -97.62% | -66.99% | $20.64 |
|
AKRO
Akero Therapeutics, Inc.
|
-- | -$0.93 | -- | -3.75% | $56.00 |
|
CABA
Cabaletta Bio, Inc.
|
-- | -$0.46 | -- | -27.29% | $14.13 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
EXEL
Exelixis, Inc.
|
$590.2M | $0.67 | 7.5% | 59.24% | $44.94 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corp.
|
$22.32 | $72.31 | $4.1B | -- | $0.00 | 0% | 4.52x |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.36 | $20.64 | $290.5M | 4.60x | $0.00 | 0% | 724.63x |
|
AKRO
Akero Therapeutics, Inc.
|
$54.65 | $56.00 | $4.5B | -- | $0.00 | 0% | -- |
|
CABA
Cabaletta Bio, Inc.
|
$2.36 | $14.13 | $227.2M | -- | $0.00 | 0% | -- |
|
CRMD
CorMedix, Inc.
|
$11.49 | $19.00 | $905.3M | 5.60x | $0.00 | 0% | 3.87x |
|
EXEL
Exelixis, Inc.
|
$40.88 | $44.94 | $11B | 17.21x | $0.00 | 0% | 5.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LEGN
Legend Biotech Corp.
|
28.86% | 1.176 | 6.82% | 2.29x |
|
ABEO
Abeona Therapeutics, Inc.
|
12.34% | -0.500 | 8.71% | 9.35x |
|
AKRO
Akero Therapeutics, Inc.
|
0.12% | 3.225 | 0.03% | 15.48x |
|
CABA
Cabaletta Bio, Inc.
|
15.6% | 6.169 | 11.44% | 3.50x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
EXEL
Exelixis, Inc.
|
7.55% | 0.460 | 1.59% | 3.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corp.
|
$151.1M | -$43.5M | -16.97% | -23.01% | -15.96% | $15.2M |
|
ABEO
Abeona Therapeutics, Inc.
|
-$1.4M | -$24M | 70.47% | 88.36% | -5698% | -$23.7M |
|
AKRO
Akero Therapeutics, Inc.
|
-- | -$90.2M | -31.13% | -32.14% | -- | -$67.2M |
|
CABA
Cabaletta Bio, Inc.
|
-$345K | -$46.6M | -90.44% | -103.46% | -- | -$34.6M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
EXEL
Exelixis, Inc.
|
$579.2M | $256.4M | 28.73% | 31.26% | 42.89% | $288.8M |
Legend Biotech Corp. vs. Competitors
-
Which has Higher Returns LEGN or ABEO?
Abeona Therapeutics, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of --. Legend Biotech Corp.'s return on equity of -23.01% beat Abeona Therapeutics, Inc.'s return on equity of 88.36%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M -
What do Analysts Say About LEGN or ABEO?
Legend Biotech Corp. has a consensus price target of $72.31, signalling upside risk potential of 223.96%. On the other hand Abeona Therapeutics, Inc. has an analysts' consensus of $20.64 which suggests that it could grow by 285.13%. Given that Abeona Therapeutics, Inc. has higher upside potential than Legend Biotech Corp., analysts believe Abeona Therapeutics, Inc. is more attractive than Legend Biotech Corp..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 ABEOAbeona Therapeutics, Inc.6 0 0 -
Is LEGN or ABEO More Risky?
Legend Biotech Corp. has a beta of 0.086, which suggesting that the stock is 91.384% less volatile than S&P 500. In comparison Abeona Therapeutics, Inc. has a beta of 1.120, suggesting its more volatile than the S&P 500 by 11.973%.
-
Which is a Better Dividend Stock LEGN or ABEO?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abeona Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. Abeona Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or ABEO?
Legend Biotech Corp. quarterly revenues are $272.7M, which are larger than Abeona Therapeutics, Inc. quarterly revenues of --. Legend Biotech Corp.'s net income of -$39.7M is lower than Abeona Therapeutics, Inc.'s net income of -$5.2M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while Abeona Therapeutics, Inc.'s PE ratio is 4.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.52x versus 724.63x for Abeona Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.52x -- $272.7M -$39.7M ABEOAbeona Therapeutics, Inc.724.63x 4.60x -- -$5.2M
-
Which has Higher Returns LEGN or AKRO?
Akero Therapeutics, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of --. Legend Biotech Corp.'s return on equity of -23.01% beat Akero Therapeutics, Inc.'s return on equity of -32.14%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B AKROAkero Therapeutics, Inc.-- -$0.99 $958.8M -
What do Analysts Say About LEGN or AKRO?
Legend Biotech Corp. has a consensus price target of $72.31, signalling upside risk potential of 223.96%. On the other hand Akero Therapeutics, Inc. has an analysts' consensus of $56.00 which suggests that it could grow by 2.47%. Given that Legend Biotech Corp. has higher upside potential than Akero Therapeutics, Inc., analysts believe Legend Biotech Corp. is more attractive than Akero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 AKROAkero Therapeutics, Inc.0 4 0 -
Is LEGN or AKRO More Risky?
Legend Biotech Corp. has a beta of 0.086, which suggesting that the stock is 91.384% less volatile than S&P 500. In comparison Akero Therapeutics, Inc. has a beta of -0.399, suggesting its less volatile than the S&P 500 by 139.855%.
-
Which is a Better Dividend Stock LEGN or AKRO?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. Akero Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or AKRO?
Legend Biotech Corp. quarterly revenues are $272.7M, which are larger than Akero Therapeutics, Inc. quarterly revenues of --. Legend Biotech Corp.'s net income of -$39.7M is higher than Akero Therapeutics, Inc.'s net income of -$81.6M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while Akero Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.52x versus -- for Akero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.52x -- $272.7M -$39.7M AKROAkero Therapeutics, Inc.-- -- -- -$81.6M
-
Which has Higher Returns LEGN or CABA?
Cabaletta Bio, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of --. Legend Biotech Corp.'s return on equity of -23.01% beat Cabaletta Bio, Inc.'s return on equity of -103.46%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B CABACabaletta Bio, Inc.-- -$0.44 $165.2M -
What do Analysts Say About LEGN or CABA?
Legend Biotech Corp. has a consensus price target of $72.31, signalling upside risk potential of 223.96%. On the other hand Cabaletta Bio, Inc. has an analysts' consensus of $14.13 which suggests that it could grow by 498.52%. Given that Cabaletta Bio, Inc. has higher upside potential than Legend Biotech Corp., analysts believe Cabaletta Bio, Inc. is more attractive than Legend Biotech Corp..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 CABACabaletta Bio, Inc.7 2 0 -
Is LEGN or CABA More Risky?
Legend Biotech Corp. has a beta of 0.086, which suggesting that the stock is 91.384% less volatile than S&P 500. In comparison Cabaletta Bio, Inc. has a beta of 3.171, suggesting its more volatile than the S&P 500 by 217.108%.
-
Which is a Better Dividend Stock LEGN or CABA?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cabaletta Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. Cabaletta Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or CABA?
Legend Biotech Corp. quarterly revenues are $272.7M, which are larger than Cabaletta Bio, Inc. quarterly revenues of --. Legend Biotech Corp.'s net income of -$39.7M is higher than Cabaletta Bio, Inc.'s net income of -$44.9M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while Cabaletta Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.52x versus -- for Cabaletta Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.52x -- $272.7M -$39.7M CABACabaletta Bio, Inc.-- -- -- -$44.9M
-
Which has Higher Returns LEGN or CRMD?
CorMedix, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of 49.9%. Legend Biotech Corp.'s return on equity of -23.01% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About LEGN or CRMD?
Legend Biotech Corp. has a consensus price target of $72.31, signalling upside risk potential of 223.96%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 65.36%. Given that Legend Biotech Corp. has higher upside potential than CorMedix, Inc., analysts believe Legend Biotech Corp. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 CRMDCorMedix, Inc.4 0 0 -
Is LEGN or CRMD More Risky?
Legend Biotech Corp. has a beta of 0.086, which suggesting that the stock is 91.384% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock LEGN or CRMD?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or CRMD?
Legend Biotech Corp. quarterly revenues are $272.7M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Legend Biotech Corp.'s net income of -$39.7M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.52x versus 3.87x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.52x -- $272.7M -$39.7M CRMDCorMedix, Inc.3.87x 5.60x $104.3M $108.6M
-
Which has Higher Returns LEGN or EXEL?
Exelixis, Inc. has a net margin of -14.57% compared to Legend Biotech Corp.'s net margin of 32.38%. Legend Biotech Corp.'s return on equity of -23.01% beat Exelixis, Inc.'s return on equity of 31.26%.
Company Gross Margin Earnings Per Share Invested Capital LEGNLegend Biotech Corp.55.42% -$0.22 $1.4B EXELExelixis, Inc.96.89% $0.70 $2.3B -
What do Analysts Say About LEGN or EXEL?
Legend Biotech Corp. has a consensus price target of $72.31, signalling upside risk potential of 223.96%. On the other hand Exelixis, Inc. has an analysts' consensus of $44.94 which suggests that it could grow by 9.94%. Given that Legend Biotech Corp. has higher upside potential than Exelixis, Inc., analysts believe Legend Biotech Corp. is more attractive than Exelixis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LEGNLegend Biotech Corp.11 1 0 EXELExelixis, Inc.9 9 0 -
Is LEGN or EXEL More Risky?
Legend Biotech Corp. has a beta of 0.086, which suggesting that the stock is 91.384% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.
-
Which is a Better Dividend Stock LEGN or EXEL?
Legend Biotech Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Legend Biotech Corp. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LEGN or EXEL?
Legend Biotech Corp. quarterly revenues are $272.7M, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Legend Biotech Corp.'s net income of -$39.7M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Legend Biotech Corp.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 17.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Legend Biotech Corp. is 4.52x versus 5.11x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LEGNLegend Biotech Corp.4.52x -- $272.7M -$39.7M EXELExelixis, Inc.5.11x 17.21x $597.8M $193.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 7.6% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.4% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 4.82% over the past day.
